<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349477</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00032587</org_study_id>
    <nct_id>NCT02349477</nct_id>
  </id_info>
  <brief_title>Gabapentin for Alcohol Relapse Prevention</brief_title>
  <official_title>Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This treatment study is a 16-weeks outpatient clinical trial where subjects with alcohol
      dependence will get medication, which might help them to reduce or stop their drinking, or a
      placebo ( placebo is a capsule that looks the same as the investigational drug, but has no
      real medication. It is a &quot;sugar pill&quot;).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This treatment study is a 16-weeks outpatient clinical trial where subjects will get
      medication, which might help them to reduce or stop their drinking or a placebo ( placebo is
      a capsule that looks the same as the investigational drug, but has no real medication. It is
      a &quot;sugar pill&quot;). This study will recruit and randomize subjects who have expressed an
      interest in receiving treatment for alcohol dependence. Upon enrollment into this study there
      will be 11 outpatient visits. Each visit will last about 1-1.5 hours.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects with no heavy drinking days (PSNHDD)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heavy drinking days per week</measure>
    <time_frame>over the 16 weeks of the study</time_frame>
    <description>The secondary dependent variable will be heavy drinking days per week over the 16 weeks of the study (4 or more standard drinks/day for women and 5 or more standard drinks/day for men). Participants will report their daily alcohol use with using a daily calendar.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin up to 1200 mg per day in 3 divided doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>gaba potentiating medication</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a pill that looks exactly like the active medication but does not contain medication</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meets criteria for alcohol use disorder based on DSM-5 criteria

          2. Meets criteria for history of alcohol withdrawal based on DSM-5 criteria

          3. Able to maintain abstinence for a minimum of 3 days prior to randomization as verified
             by self report, urine ETG, and breathalyzer.

        Exclusion Criteria:

          1. Significant psychiatric or medical illness

          2. No other substance abuse

          3. Taking other medications known to treat alcohol use disorder

          4. Unstable living arrangements

          5. Significant legal problems pending
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond F Anton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

